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Role of 'catalytic' iron in an animal model of minimal change nephrotic
syndrome. Treatment of minimal change disease, like most glomerulone-
phritides, is empirical because underlying mechanisms that cause glomer-
ular injury are not known. We examined a pathogenic role of 'catalytic'
iron in a model of minimal change nephrotic syndrome induced by
injection of puromycin aminonucleoside (7.5 mgIlOO g body wt) to rats.
Although there was no significant change in non-heme iron content in
glomeruli, the bleomycin-detectable iron (capable of catalyzing free
radical reactions) was markedly increased in glomeruli from nephrotic rats
when compared to control. In contrast, despite a marked and significant
increase in the non-heme iron content in tubules, there was no significant
change in the bleomycin-detectable iron in tubules from nephrotic rats. In
a separate in vivo study, the iron chelator, deferoxamine, prevented the
increase in the bleomycin-detectable iron in glomeruli and provided
complete protection against proteinuria. Taken together, our data suggest
an important pathogenetic role for glomerular catalytic iron in the
puromycin aminonucleoside-induced minimal change nephrotic syn-
drome.
Minimal change nephrotic syndrome accounts for more than
75% of cases of nephrotic syndrome in children and 20 to 30% of
nephrotic syndrome in adults [1—3]. Treatment of minimal change
disease, like most glomerulonephritides, is empirical because
underlying mechanisms that cause glomerular injury are not
known. Thus, corticosteroids and, in patients who frequently
relapse or are refractory to corticosteroids, immunosuppressive
drugs are often used to treat minimal change disease [1—3]. A
better understanding of the mechanisms of glomerular diseases
may lead to treatment which is not associated with the complica-
tions of corticosteroids and immunosuppressive drugs.
Recent studies indicate an important role of iron in tissue injury
[4]. The ease with which iron is reversibly oxidized and reduced,
while essential for its metabolic functions also makes iron poten-
tially hazardous because of its ability to participate in the gener-
ation of powerful oxidant species, hydroxyl radical [4] (the metal
catalyzed Haber-Weiss reaction), and/or in the generation of the
highly reactive iron-oxygen complexes such as ferryl or perferryl
ion [4]. However, in vivo most of the iron is bound to heme and
non-heme proteins, and does not directly catalyze the generation
of hydroxyl radicals or a similar oxidant [41. Gutteridge et al have
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described an assay, based on the use of the antibiotic, bleomycin,
to detect iron complexes capable of catalyzing free radical reac-
tions in biological samples [4—7]. This assay has been largely
applied to biological fluids such as plasma [7], synovial fluid [81,
and cerebral spinal fluid [7]. Recently, in a limited number of
studies this assay has been used to demonstrate an increase in iron
capable of catalyzing free radical reactions in tissues [5, 9].
Although several studies indicate a role of reactive oxygen
metabolites in glomerular diseases reviewed in [10], there is no
information of whether iron capable of catalyzing free radical
reactions is increased in models of glomerular diseases. A single
intravenous injection of puromycin aminonucleoside to rats re-
sults in massive proteinuria and glomerular morphological
changes that are similar to minimal change nephrotic syndrome in
humans [11]. In the present study, we examined the non-heme and
'catalytic' iron content in glomeruli and tubules in this model of
glomerular disease. To examine a pathogenic role of iron, we
determined the in vivo effect of an iron chelator, deferoxamine, on
'catalytic' iron and proteinuria.
Methods
Male Sprague-Dawley rats were injected with either saline or a
single intravenous injection of puromycin aminonucleoside in a
dose of 7.5 mg/100 g body wt to induce nephrotic syndrome (day
0) as in our previous studies [12]. In a separate experiment, an
iron chelator, deferoxamine B mesylate (Desferal, Ciba-Geigy),
was administered intravenously in a dose of 30 mg/rat the evening
prior to the puromycin aminonucleoside injection. At the same
time, deferoxamine was administered via osmotic pump (Alza
Corp, Palo Alto, CA, USA) implanted subcutaneously. The drug
was reconstituted in water at a concentration of 250 mg/mI, and
the pumps (with a 2 ml capacity) delivered approximately 30 mg
deferoxamine per rat per day at a continuous rate of 5 pd/hr. The
iron chelator was administered until sacrifice.
At the time of sacrifice, kidneys were perfused with ice-cold
Chelex-treated 0.9% NaCI, and glomeruli and tubules were
isolated using Chelex-treated 0.9% NaCI by a combination of
differential sievings and centrifugation as previously described
[13]. Glomeruli and tubules obtained from two rats (considered
an N of 1) were pooled together for determination of the
non-heme iron and the bleomycin-detectable iron. For tissue iron
determinations all buffers and reagents except for the test sample
were made up in Chelex-treated deionized water and treated with
Chelex again in iron-free plastic containers to remove as much
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contaminating iron as possible. Isolated glomeruli or tubules were
pelleted by centrifugation at 4°C and 700 g for 10 minutes and
resuspended in 1 ml of Chelex-treated deionized water. They were
sonicated three times for five seconds on ice at a power output of
40 W, and centrifuged at 14000 g for 15 minutes. The supernatants
were used for the iron and protein measurement. The amount of
bleomycin-detectable iron in the test samples was measured as
previously described [5—7, 91. The reaction mixture contained 0.5
ml calf thymus DNA (1 mg/mI), 0.05 ml bleomycin sulfate (1
U/mI), 0.1 ml MgCI2 (50 mM), 0.1 ml sample, and 0.1 ml ascorbic
acid solution. The pH of the reaction mixtures was adjusted to 7.2
to 7.8 using the appropriate amount of 25 mrvi NaOH before
running the assay. Sample blanks were identical except that
bleomycin was omitted. Tubes were mixed and incubated at 37°C
for two hours with shaking. The reaction was stopped by adding
0.1 ml EDTA (0.1 M), followed by the addition of 1 ml thiobar-
bituric acid (1% wt/vol in 50 mri NaOH) and HC1 (25% vol/vol).
The samples were heated at 100°C for 15 minutes, cooled and the
resulting chromogen measured by its absorbance at 532 nm using
a spectrophotometer. Standard iron solutions were prepared
using various concentrations of ferric chloride (0, 3.125, 6.25, 12.5,
25, and 50 nmol per 0.1 ml) in Chelex-treated deionized water.
Each standard also had a corresponding blank that was identical
except that bleomycin was omitted. The absorbance of the zero
standard (which contained only Chelex-treated deionized water as
a standard), reflecting iron contamination in the reagents, etc.,
was subtracted from all standards to construct the standard curve.
The amount of bleomycin-detectable iron in the test samples was
calculated from the standard curve obtained in each experiment
as in our previous study [9]. The amount of bleomycin-detectable
iron in glomeruli and tubules was calculated and the data ex-
pressed as nmol per mg protein.
Hematocrit, blood urea nitrogen, serum creatinine, serum iron,
and non-heme iron were measured as described [9]. Protein
measurement for urine and supernatant of the tissues was per-
formed by the Bio-Rad protein assay.
Results are expressed as means standard error of mean.
Statistical analysis was performed using unpaired Student's t-test
and P < 0.05 was considered significant.
Puromycin aminonucleoside was purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA). Bleomycin sulfate was purchased
from Bristol Myers Squibb Co. (Princeton, NJ, USA), and Chelex-
100 was obtained from Bio-Rad Laboratories (Richmond, CA,
USA). All other chemicals were obtained from Sigma Chemical
Co.
Results
The time course of proteinuria in the rats injected with
puromycin aminonucleoside in a dose of 7.5 mg/100 g body wt is
shown in Figure 1. Significant proteinuria was first apparent on
day 4 which rapidly increased thereafter, reaching 279 37 mg/24
hours on day 7 (N = 20) as in our previous study [12]. On day 7
there were no differences in body wt, hematocrit, serum iron and
renal function in the nephrotic rats as compared to control (Table
1). However, there was a significant increase in the non-heme iron
in kidney cortex in the nephrotic rats as compared to control (N
= 10, P < 0.001).
Because the major target in puromycin aminonucleoside-in-
duced nephrotic syndrome is the glomerulus, in a separate
experiment we examined the non-heme iron content in both
glomeruli and tubules. In rats injected with puromycin, 24-hour
urinary protein increased from 22 2 to 426 49 mg124 hr (P <
0.005). As shown in Figure 2, there was a significant increase in
the non-heme iron content in the tubules obtained from the
nephrotic rats (from 229 49 to 424 25 nmol/mg protein, N =
4, P < 0.001) when compared to control, but no change observed
in glomeruli (control 191 15 vs. puromycin aminonucleoside
195 19 nmol/mg protein).
In our previous study we have shown that catalytic iron may
increase even without any alterations in the total or non-heme
iron [9]. Therefore, we next examined the bleomycin-detectable
iron content in glomeruli and tubules obtained from rats injected
with puromycin aminonucleoside. Despite no changes in the
non-heme iron in the glomeruli, there was a marked increase in
the bleomycin-detectable iron in glomeruli on day 7 (Fig. 3, from
46 3 to 123 10 nmol/mg protein, N = 10,P < 0.0001). We also
determined bleomycin-detectable iron at an early time point.
Bleomycin-detectable iron was increased in glomeruli as early as
day 4 (from 45 8 to 61 6 nmol/mg protein, N = 6, P < 0.05).
Interestingly, even with a marked increase in non-heme iron, no
change in the bleomycin-detectable iron was observed in tubules.
To examine the pathogenic role of an increase in the bleomy-
cm-detectable iron in glomeruli in puromycin aminonucleoside-
induced nephrotic syndrome, we carried out an in vivo study to
determine the effect of an iron chelator, deferoxamine, on puro-
mycin aminonucleoside-induced increase in the bleomycin-detect-
able iron in glomeruli and on proteinuria. Deferoxamine com-
pletely prevented the increase in the bleomycin-detectable iron in
glomeruli obtained from the puromycin aminonucleoside-treated
rats and provided complete protection against proteinuria (Fig.
4).
Discussion
Sequential reduction of oxygen along the univalent pathway
leads to the generation of superoxide anion, hydrogen peroxide,
hydroxyl radical, and water [4]. Puromycin aminonucleoside which
induces minimal change nephrotic syndrome in rats has been
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Fig. 1. Time course of urine protein excretion in control (LI, N = 23) and
puromycin aminonucleoside (7.5 mg/100 g body wt)-treated rats • N =
20). Results are means SEM. *P < 0.01, < 0.001, compared to
control.
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Table 1. Data from rats fed a normal iron diet and injected with either saline or puromycin aminonucleoside (PAN)
Weight Hematocrit Serum iron
Blood urea
nitrogen
Serum
creatinine
Kidney non-heme iron
g % pmol/dl mg/dl mol/g tissue
Control 297 5 46 2 3.4 0.1 22 1 0.45 0.02 0.63 0.03
(23) (12) (12) (23) (23) (12)
PAN 292 8 46 1 3.1 0.2 25 1 0.49 0.04 1.27 0.07
(20) (10) (10) (20) (20) (10)
Results are from one to three separate experiments and expressed as means SEM. The number of animals used is in parenthesis.
aP < 0.001 compared to the saline-injected control
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Fig. 2. Non-heme iron in glomendi and tubules from rats injected with
puromycin aminonucleoside. Results were obtained on day 7 after puro-
mycin aminonucleoside injection and expressed as means SEM. ap <
0.001, compared to control. Shown are control (LI); puromycin amino-
nucleoside-injeeted rats (L).
shown to enhance production of superoxide anion and hydrogen
peroxide [14]. Superoxide and hydrogen peroxide, in the presence
of iron, generate more powerful oxidant species such as hydroxyl
radicals and/or highly reactive iron-oxygen complexes such as
ferryl or perferryl ion [4] leading to tissue injury. However, an
increase in 'catalytic' iron has not been demonstrated in any
model of glomerular injury.
We examined whether an increase in 'catalytic' iron, could be
demonstrated in the glomeruli in a model of minimal change
disease using the bleomycin-detectable iron assay. The assay is
based on the observation that the anti-tumor antibiotic, bleomy-
cm, which in the presence of an iron salt and a suitable reducing
agent, binds to and degrades DNA with the formation of a
product that reacts with thiobarbituric acid to form a chromogen.
The binding of the bleomycin-iron complex to the DNA makes
the reaction site specific and antioxidants rarely interfere with this
reaction. Iron detected in this assay is, thus, a measure of iron
available from the biological sample to bleomycin. The assay
conditions have been designed to prevent any interference from
iron-proteins [4—71. Iron bound to transferrin, lactoferrin, ferritin
or iron-containing enzymes does not register in the bleomycin
assay [4—71.
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Fig. 3. Bleomycin-detectable iron in glomeruli and tubules from rats injected
with puromycin aminonucleoside. Data were obtained on day 7 after
puromycin aminonucleoside injection from two separate experiments and
expressed as means SEM. < 0.0001, compared to control. Shown are
control (LI); puromycin aminonucleoside-injected rats ().
In the present study, we demonstrate that although there is no
change in the non-heme iron content in glomeruli, there is a
marked increase in bleomycin-detectable iron (capable of cata-
lyzing free radical reactions) in glomeruli. In contrast, despite a
marked increase in the non-heme iron content in tubules, there
was no increase in bleomycin-detectable iron in the tubules. This
observation that non-heme iron is increased in the tubules is in
keeping with the recent report which demonstrated an increase in
renal cortical iron in this model of glomerular disease [15]. The
iron chelator, deferoxamine, prevented an increase in the bleo-
mycin-detectable iron in glomeruli and provided complete pro-
tection against proteinuria. Taken together, these data suggest
that the 'catalytic' iron plays an important role in the pathogenesis
of this model of minimal change disease.
Deferoxamine has been widely used to prevent iron-overload in
human diseases [161. However, by chelating iron, deferoxamine
also prevents the generation of hydroxyl radical and other iron-
dependent oxidant species [4]. Thus, deferoxamine and other iron
chelators have the therapeutic potential in which oxidant mecha-
nisms have been implicated to play a role. Indeed, an iron chelator
has been shown to prevent adriamycin-induced cardiomyopathy
[17] in which oxidant mechanisms have been implicated. There
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